Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven H Bernstein

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Experimental Hematology|December 3, 2014
Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approachMichelle Kiebala, Jolanta Skalska, Carla Casulo, et al.
Blood|October 13, 2006
CpG DNA activation and plasma-cell differentiation of CD27- naive human B cellsJennifer Huggins, Tina Pellegrin, Raymond E Felgar, et al.
Cancer Research|February 20, 2007
The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and its derivatives elicit human lymphoid cell apoptosis through a novel pathway involving the unregulated mitochondrial permeability transition porePaul S Brookes, Kimberly Morse, Denise Ray, et al.
Plos One|December 4, 2009
Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolideJolanta Skalska, Paul S Brookes, Sergiy M Nadtochiy, et al.
Blood Advances|January 4, 2018
Patient-derived xenografts of low-grade B-cell lymphomas demonstrate roles of the tumor microenvironmentW Richard Burack, Janice M Spence, John P Spence, et al.
Leukemia & Lymphoma|June 25, 2010
Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trialAndré Goy, Steven H Bernstein, Alice McDonald, et al.
Blood|February 7, 2009
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximabShannon P Hilchey, Ollivier Hyrien, Tim R Mosmann, et al.
Blood|February 11, 2012
The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivativesSteven H Bernstein, Sundararajan Venkatesh, Min Li, et al.
Blood|December 15, 2007
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignanciesNancy L Bartlett, Anas Younes, Matthew H Carabasi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2013
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomasJonathan W Friedberg, Daruka Mahadevan, Erin Cebula, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Experimental Hematology|December 3, 2014
Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approachMichelle Kiebala, Jolanta Skalska, Carla Casulo, et al.
Blood|October 13, 2006
CpG DNA activation and plasma-cell differentiation of CD27- naive human B cellsJennifer Huggins, Tina Pellegrin, Raymond E Felgar, et al.
Cancer Research|February 20, 2007
The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and its derivatives elicit human lymphoid cell apoptosis through a novel pathway involving the unregulated mitochondrial permeability transition porePaul S Brookes, Kimberly Morse, Denise Ray, et al.
Plos One|December 4, 2009
Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolideJolanta Skalska, Paul S Brookes, Sergiy M Nadtochiy, et al.
Blood Advances|January 4, 2018
Patient-derived xenografts of low-grade B-cell lymphomas demonstrate roles of the tumor microenvironmentW Richard Burack, Janice M Spence, John P Spence, et al.
Leukemia & Lymphoma|June 25, 2010
Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trialAndré Goy, Steven H Bernstein, Alice McDonald, et al.
Blood|February 7, 2009
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximabShannon P Hilchey, Ollivier Hyrien, Tim R Mosmann, et al.
Blood|February 11, 2012
The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivativesSteven H Bernstein, Sundararajan Venkatesh, Min Li, et al.
Blood|December 15, 2007
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignanciesNancy L Bartlett, Anas Younes, Matthew H Carabasi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2013
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomasJonathan W Friedberg, Daruka Mahadevan, Erin Cebula, et al.
Pageof 6